NYSE:EWMedical Equipment
Did Higher 2026 TAVR Guidance and Autus Deal Just Shift Edwards Lifesciences' (EW) Investment Narrative?
Edwards Lifesciences recently raised its full-year 2026 sales and TAVR growth guidance and completed the acquisition of Autus Valve Technologies, further expanding its structural heart portfolio beyond TAVR.
This combination of higher guidance and broader coverage across aortic, mitral, and tricuspid therapies underscores how Edwards is deepening its role in treating complex structural heart disease.
Next, we’ll examine how the upgraded sales outlook, particularly for TAVR, may reshape...